Delivery Order SPE2DB22D1202-SPE2DB25FVFY6
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packages) with a ceiling value of $13,483.05. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a non-set-aside, competitively awarded contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitive award, with a ceiling value of $1,781.89, utilizes firm fixed-price delivery order terms and is scheduled for completion by July 23, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4mg in a quantity of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $40,007.36 and an ultimate completion date of August 18, 2025. The contract is not designated as a set-aside and represents a competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $6,633.04. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procurement and is scheduled for completion by July 28, 2025. The products will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package, with a ceiling value of $4,539.09 and a completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. Ondansetron is an antiemetic...
- The Defense Logistics Agency awarded a delivery order valued at approximately $26,000 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on July 18, 2025, with completion expected by July 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ondansetron is an antiemetic medication commonly used in...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $4,328.04 under firm fixed-price terms, with an ultimate completion date of July 31, 2025. The pharmaceutical products will be delivered to the contracting location in Conshohocken, Pennsylvania, where...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 22, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $7,069.80 and an ultimate completion date of July 23, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. Performance will be executed from the contractor's location in Conshohocken,...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVFY6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a ceiling value of $13,127.44. This contract employs firm fixed price terms and carries an ultimate completion date of July 31, 2025. The award utilized no set-aside designation, indicating competitive procurement through open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—which also serves as the place of performance—is a major pharmaceutical distributor and critical federal vendor for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including deliveries to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Ondansetron, a commonly used antiemetic medication, addresses pharmaceutical needs within the company's extensive portfolio of brand-name and generic medications covering multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.1k | 7/30/25 |